Editorial
Copyright ©The Author(s) 2024.
World J Diabetes. Jun 15, 2024; 15(6): 1060-1069
Published online Jun 15, 2024. doi: 10.4239/wjd.v15.i6.1060
Table 1 Boron-containing compounds exert effects similar to those described for drugs currently used as therapy in diabetes patients
Type of drug
Example in use
BCC acting in a similar or related way
Ref.
BiguanidesMetforminBoron-containing biguanides have been synthesized and some have shown biological effects. Some BCC is being used in biomaterials for metformin releaseAnderson et al[59], 1995; Ghosh et al[60], 1998; Lai et al[61], 2023
GLP-1 receptor agonistExenatideNo BCC has been designed with a structural analogy to known GLP-1 agonists. However, some BCC seems to be able to modify the incretins serum levelsDas et al[9], 2022; Ri et al[7], 2023
DPP-IV inhibitorsSitagliptinDutogliptin, talabostat, PC06R58, and PC06R108 are potent uncompetitive DPP-IV inhibitorsWu et al[55], 2021; Prajapati et al[62], 2024
SGLT2 inhibitorsDapagliflozinDX-B-DA, a fluorophore-dapagliflozin dyad has been tested as theranostic agent. It can bind the SGLT2Yu et al[63], 2021
SulfonylureasGlibenclamideGlibenclamide-BCC acts as a high-affinity blocker of pancreatic β-cell KATP currents. Non-specific binding limited its useZünkler et al[64], 2004
α-glucosidase inhibitorAcarboseSome azaborininones exhibit moderate to good inhibitory effects against glucosidase to acarbose used as a reference standardMphahlele et al[65], 2021
InsulinInsulinSeveral BCC result in changes in insulin serum concentrations. Boric acid and phenylboronic acids diminish the increase of insulin release (and the total weight of visceral fat) in rats exposed to a high-fat diet and streptozotocin. The insulin release could be controlled by complexes with boronic acidsLópez-Cabrera et al[42], 2018; Banach et al[21], 2021; Kikuchi et al[66], 2021